Advertisement

Therapeutische Beeinflussung des Belastungsblutdrucks und Wirksamkeit auf Kardiovaskuläre Hochdruck komplikationen — Hypothesen und Beweise

  • Th. Philipp
Conference paper

Zusammenfassung

Das Thema dieser Übersicht impliziert bereits, daß es keine eindeutigen Beweise dafür gibt, daß eine spezielle therapeutische Beeinflussung des Belastungsblutdruckes zur Reduktion der kardiovaskulären Übersterblichkeit bei Hypertonie führt, Beweise, die Hypothesen überflüssig machen würden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Society of Actuaries (1959) Build and Blood pressure Study, Vol. 1 Chicago, Society of ActuariesGoogle Scholar
  2. 2.
    Metropolitan Life Insurance Company (1961) Blood pressure: insurance experience and its implications. Metropolitan Life Insurance C., New YorkGoogle Scholar
  3. 3.
    Dawber TR, Kannel WB (1972) Current status of coronary prevention. Prey Med 1: 499–512CrossRefGoogle Scholar
  4. 4.
    Irving JB, Bruce RA, De Rouen TA (1977) Variations in and significance of systolic pressure during maximal exercise testing. Am J Cardiol 39: 841–849PubMedCrossRefGoogle Scholar
  5. 5.
    Bruce RA, Peterson DR, De Rouen TA (1977) Noninvasive predictors of sudden cardiac death in men with coronary heart disease. Am J Cardiol 39: 833–840PubMedCrossRefGoogle Scholar
  6. 6.
    Anlauf M (1984) Der Belastungsblutdruck als diagnostischer Test — Sensitivität and Spezifität. (s. dieser Band)Google Scholar
  7. 7.
    Dlin RA, Hanne N, Silverberg DS, Bar-Or 0 (1983) Follow-up of normotensive men with exaggerated blood pressure response to exercise. Am Heart J 106: 316–320Google Scholar
  8. 8.
    Perloff D, Sokdow M, Cowan R (1983) The prognostic value of ambulatory blood pressures. JAMA 249: 2792–2798PubMedCrossRefGoogle Scholar
  9. 9.
    Gotzen R (1984) Der Effekt von Antihypertensiva auf den Belastungsblutdruck. (s. dieser Band)Google Scholar
  10. 10.
    Middeke M, Holzgreve H (1983) Blutdruckverhalten während isometrischer and dynamischer Belastung unter antihypertensiver Langzeittherapie mit Beta-Rezeptorenblockern and Diuretika. Kli Wschr 61: 1241–1248CrossRefGoogle Scholar
  11. 11.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension (1967) Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 202: 1028–1034Google Scholar
  12. 12.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension (1970) II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 213: 1143–1152Google Scholar
  13. 13.
    Hypertension Detection and Follow-up program Cooperative Group (1979) Five-year findings of the Hypertension Detection and Follow-up Program: II. Mortality by race-sex and age. JAMA 242: 2572–2577CrossRefGoogle Scholar
  14. 14.
    Hypertension Detection and Follow-up Program Cooperative Group (1979) Five-year findings of the Hypertension Detection and Follow-up Program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 242: 2562–2571CrossRefGoogle Scholar
  15. 15.
    Australian National Blood Pressure Study (1980) The Australian Therapeutic Trial in Mild Hypertension. Lancet 1980 I: 1261–1267Google Scholar
  16. 16.
    Wilhelmsson C, Vedin JA, Wilhelmsen L et al. (1974) Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. Lancet 2: 1157Google Scholar
  17. 17.
    Andersen MP, Bechsgaard P, Frederiksen J et al. (1979) Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Lancet 2: 865PubMedCrossRefGoogle Scholar
  18. 18.
    Barber JM, Boyle DMcC, Chaturvedi NC et al. (1975) Practolol in acute myocardial infarction. Acta Med Scand Suppl 587: 213Google Scholar
  19. 19.
    Multicentre International Study (1977) Reduction in mortality after myocardial infarction with long-term betaadrenoceptor blockade. Supplementary Report. Br Med J 2: 419CrossRefGoogle Scholar
  20. 20.
    Baber NS, Wainwright-Evans D, Howitt D et al. (1980) Multicenter postinfarction trial of propranolol in 49 hospitals in the United Kingdom, Italy and Yugoslavia. Br Heart J 44: 96PubMedCrossRefGoogle Scholar
  21. 21.
    Beta-Blocker Heart Attack Trial Study Group (1981) Beta-Blocker Heart Attack Trial. Preliminary report JAMA 246: 2073Google Scholar
  22. 22.
    The Norwegian Multicenter Study Group (1981) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304: 801CrossRefGoogle Scholar
  23. 23.
    The European Infarction Study Group (1984) A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. Europ Heart J 5: 189Google Scholar
  24. 24.
    Wilcox RG, Roland JM, Banks DC et al. (1980) Randomized trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction. Br Med J 1: 885CrossRefGoogle Scholar
  25. 25.
    Andersen MP, Frederiksen J, Jürgensen HJ, Pedersen F, Bechsgaard P, Hansen DA, Nielsen B, Pedersen-Bjergaard O, Rasmussen SL (1979) Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Lancet: 865Google Scholar
  26. 26.
    Report of Medical Research Council Working Party on Mild to Moderate Hypertension (1981) Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet 2: 539Google Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1984

Authors and Affiliations

  • Th. Philipp
    • 1
  1. 1.Medizinische Klinik und PoliklinikUniversitätsklinikum SteglitzBerlin 45Deutschland

Personalised recommendations